Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "rating"

2025 News Found

Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review
News | May 18, 2026

Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review

The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million


Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion
Hospitals | May 18, 2026

Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion

Medanta expanded its bed capacity by 20% during the year


WFNS opens doors to industry in landmark Neurosurgery Innovation Pact with Time Med
News | May 16, 2026

WFNS opens doors to industry in landmark Neurosurgery Innovation Pact with Time Med

The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers


Telangana life sciences ecosystem reaches $145 billion valuation
Biotech | May 15, 2026

Telangana life sciences ecosystem reaches $145 billion valuation

The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters


Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore
News | May 15, 2026

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore

The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives


OneSource records Rs. 4,282 million revenue in Q4 FY26
News | May 15, 2026

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold


Senores Pharma doubles profit as sales surge 62%
News | May 15, 2026

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth


Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push
News | May 14, 2026

Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push

Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support